Mölndal, Sweden, May 21, 2025 - Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has entered a distribution agreement with Bionics Group Ukraine, LLC., a niche distributor-integrator of medical equipment for hospitals and private clinics in Ukraine. The agreement covers units that are used in the surgical implantation (S1 and S2 procedures) of the OPRA® Implant System.
Integrum has been present in Ukraine since May 2023, when the first prosthetic procedures using the OPRA® Implant System were performed by Dr. Rickard Brånemark. In December 2023, the company contributed to establishing a center of excellence for trauma care in Kyiv, with the aim to spearhead orthopedic treatments with the OPRA® Implant System in individuals who had suffered limb loss. Since then, approximately 80 patients have been treated with the implant system at the center.
The medical need remains high, as approximately 100,000 Ukrainians require treatment due to limb loss. To help address this issue and build a durable, long-term care infrastructure, the company targets critical bottlenecks by training medical personnel in the use of the OPRA® Implant System; thereby deepening the knowledge in endoprosthetic treatments and broadening the clinical experience of osseointegration technology.
The agreement with Bionics Group Ukraine, LLC, includes the full Integrum OPRA® Implant System suite, including AxorÔ II Prosthesis Connection Device and orthopedic devices used in humerus and digit implantations. This creates an opportunity for the company to formalize its distribution processes in Ukraine and take one step further in laying the foundation for a potential delivery chain scale-up.
"Our agreement with Bionics Group Ukraine is especially encouraging as Integrum has played an important role historically in supporting the establishment of state-of-the-art treatment facilities for patients who have suffered limb loss in Ukraine. The broadened distribution of our OPRA® Implant System strengthens the company's presence further in the region, and it is an important step going forward and we see the long-term value in supporting medical specialists and regulatory agencies to build a robust and modernized healthcare infrastructure," comments Martin Hillsten, CEO of Integrum.